B of A Securities Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $8
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
B of A Securities analyst Jason Zemansky maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and lowers the price target from $10 to $8.
B of A Securities analyst Jason Zemansky maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and lowers the price target from $10 to $8.